The influence of neuroinflammation on neuronal function and hippocampal atrophy in Alzheimer’s disease (AD) and Parkinson’s disease dementia (PDD) is still unclear.
Objectives:
Here we investigated whether microglial activation measured by [11C]PK11195 PET is associated with neuronal function measured by cerebral glucose metabolic rate (rCMRGlc) using FDG-PET and hippocampal volume measurements.
Methods:
We enrolled 25 subjects (9 PDD, 8 AD, and 8 controls) who underwent PET scans with [11C](R)PK11195, [18F]FDG, and volumetric MRI scanning.
Results:
SPM correlation analysis in AD and PDD showed a negative correlation between hippocampal volume and microglial activation within hippocampus or parahippocampus and with cortical and subcortical areas of projections from hippocampus, while there was a positive correlation between rCMRGlc in cortical and subcortical areas of projections from hippocampus and hippocampal volume. Hippocampal volume was significantly reduced in AD compared to controls but not in PDD.
Conclusions:
These findings indicate that microglial activation inversely correlated with hippocampal volume and hippocampal rCMRGlc in neurodegenerative diseases with dementia, providing further evidence for the central role of microglial activation in neurodegenerative diseases.
MoralesI, Guzman-MartinezL, Cerda-TroncosoC, FariasGA, MaccioniRB (2014) Neuroinflammation in the pathogenesis of Alzheimer’s disease. A rational framework for the search of novel therapeutic approaches. Front Cell Neurosci8, 112.
2.
HanischUK, KettenmannH (2007) Microglia: Active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci10, 1387–1394.
3.
LiuB, HongJS (2003) Role of microglia in inflammation-mediated neurodegenerative diseases: Mechanisms and strategies for therapeutic intervention. J Pharmacol Exp Ther304, 1–7.
4.
Frank-CannonTC, AltoLT, McAlpineFE, TanseyMG (2009) Does neuroinflammation fan the flame in neurodegenerative diseases?. Mol Neurodegener4, 47–.
5.
EdisonP, ArcherHA, GerhardA, HinzR, PaveseN, TurkheimerFE, HammersA, TaiYF, FoxN, KennedyA, RossorM, BrooksDJ (2008) Microglia, amyloid, and cognition in Alzheimer’s disease: An [11C](R)PK11195-PET and [11C]PIB-PET study. Neurobiol Dis32, 412–419.
6.
CagninA, GerhardA, BanatiRB (2002) In vivo imaging of neuroinflammation. Eur Neuropsychopharmacol12, 581–586.
7.
EdisonP, AhmedI, FanZ, HinzR, GelosaG, Ray ChaudhuriK, WalkerZ, TurkheimerFE, BrooksDJ (2013) Microglia, amyloid, and glucose metabolism in Parkinson’s disease with and without dementia. Neuropsychopharmacology38, 938–949.
8.
LeungKK, BartlettJW, BarnesJ, ManningEN, OurselinS, FoxNC, Alzheimer’s Disease Neuroimaging Initiative (2013) Cerebral atrophy in mild cognitive impairment and Alzheimer disease: Rates and acceleration. Neurology80, 648–654.
BeyerMK, JanvinCC, LarsenJP, AarslandD (2007) A magnetic resonance imaging study of patients with Parkinson’s disease with mild cognitive impairment and dementia using voxel-based morphometry. J Neurol Neurosurg Psychiatry78, 254–259.
11.
CamicioliR, MooreMM, KinneyA, CorbridgeE, GlassbergK, KayeJA (2003) Parkinson’s disease is associated with hippocampal atrophy. Mov Disord18, 784–790.
12.
LaaksoMP, PartanenK, RiekkinenP, LehtovirtaM, HelkalaEL, HallikainenM, HanninenT, VainioP, SoininenH (1996) Hippocampal volumes in Alzheimer’s disease, Parkinson’s disease with and without dementia, and in vascular dementia: An MRI study. Neurology46, 678–681.
13.
ApostolovaLG, BeyerM, GreenAE, HwangKS, MorraJH, ChouYY, AvedissianC, AarslandD, JanvinCC, LarsenJP, CummingsJL, ThompsonPM (2010) Hippocampal, caudate, and ventricular changes in Parkinson’s disease with and without dementia. Mov Disord25, 687–695.
14.
McKhannGM, KnopmanDS, ChertkowH, HymanBT, JackCRJr, KawasCH, KlunkWE, KoroshetzWJ, ManlyJJ, MayeuxR, MohsRC, MorrisJC, RossorMN, ScheltensP, CarrilloMC, ThiesB, WeintraubS, PhelpsCH (2011) The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 263–269.
15.
EmreM (2003) Dementia associated with Parkinson’s disease. Lancet Neurol2, 229–237.
16.
FischlB, van der KouweA, DestrieuxC, HalgrenE, SegonneF, SalatDH, BusaE, SeidmanLJ, GoldsteinJ, KennedyD, CavinessV, MakrisN, RosenB, DaleAM (2004) Automatically parcellating the human cerebral cortex. Cereb Cortex14, 11–22.
17.
FischlB, SalatDH, BusaE, AlbertM, DieterichM, HaselgroveC, van der KouweA, KillianyR, KennedyD, KlavenessS, MontilloA, MakrisN, RosenB, DaleAM (2002) Whole brain segmentation: Automated labeling of neuroanatomical structures in the human brain. Neuron33, 341–355.
18.
TurkheimerFE, EdisonP, PaveseN, RoncaroliF, AndersonAN, HammersA, GerhardA, HinzR, TaiYF, BrooksDJ (2007) Reference and target region modeling of [11C]-(R)-PK11195 brain studies. J Nucl Med48, 158–167.
19.
AndersonAN, PaveseN, EdisonP, TaiYF, HammersA, GerhardA, BrooksDJ, TurkheimerFE (2007) A systematic comparison of kinetic modelling methods generating parametric maps for [(11)C]-(R)-PK11195. Neuroimage36, 28–37.
20.
FanZ, AmanY, AhmedI, ChetelatG, LandeauB, Ray ChaudhuriK, BrooksDJ, EdisonP (2015) Influence of microglial activation on neuronal function in Alzheimer’s and Parkinson’s disease dementia. Alzheimers Dement11, 608–621. e7.
21.
KreislWC, LyooCH, McGwierM, SnowJ, JenkoKJ, KimuraN, CoronaW, MorseCL, ZoghbiSS, PikeVW, McMahonFJ, TurnerRS, InnisRB, Biomarkers Consortium PET Radioligand Project Team (2013) In vivo radioligand binding to translocator protein correlates with severity of Alzheimer’s disease. Brain136, 2228–2238.
22.
KreislWC, FujitaM, FujimuraY, KimuraN, JenkoKJ, KannanP, HongJ, MorseCL, ZoghbiSS, GladdingRL, JacobsonS, OhU, PikeVW, InnisRB (2010) Comparison of [(11)C]-(R)-PK 11195 and [(11)C]PBR28, two radioligands for translocator protein (18 kDa) in human and monkey: Implications for positron emission tomographic imaging of this inflammation biomarker. Neuroimage49, 2924–2932.
23.
DoensD, FernandezPL (2014) Microglia receptors and their implications in the response to amyloid beta for Alzheimer’s disease pathogenesis. J Neuroinflammation11, 48.
24.
ImamuraK, HishikawaN, SawadaM, NagatsuT, YoshidaM, HashizumeY (2003) Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson’s disease brains. Acta Neuropathol106, 518–526.
25.
PradhanS, AndreassonK (2013) Commentary: Progressive inflammation as a contributing factor to early development of Parkinson’s disease. Exp Neurol241, 148–155.
26.
ChungCY, KoprichJB, SiddiqiH, IsacsonO (2009) Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV alpha-synucleinopathy. J Neurosci29, 3365–3373.
27.
TangY, LeW (2016) Differential roles of M1 and M2 microglia in neurodegenerative diseases. Mol Neurobiol53, 1181–1194.
28.
MillsCD, KincaidK, AltJM, HeilmanMJ, HillAM (2000) M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol164, 6166–6173.
29.
Koenigsknecht-TalbooJ, LandrethGE (2005) Microglial phagocytosis induced by fibrillar beta-amyloid and IgGs are differentially regulated by proinflammatory cytokines. J Neurosci25, 8240–8249.
30.
CherryJD, OlschowkaJA, O’BanionMK (2014) Neuroinflammation and M2 microglia: The good, the bad, and the inflamed. J Neuroinflammation11, 98.
AmorS, PuentesF, BakerD, van der ValkP (2010) Inflammation in neurodegenerative diseases. Immunology129, 154–169.
33.
FemminellaGD, RengoG, PaganoG, de LuciaC, KomiciK, ParisiV, CannavoA, LiccardoD, VigoritoC, FilardiPP, FerraraN, LeoscoD (2013) beta-adrenergic receptors and G protein-coupled receptor kinase-2 in Alzheimer’s disease: A new paradigm for prognosis and therapy?. J Alzheimers Dis34, 341–347.
34.
Jardanhazi-KurutzD, KummerMP, TerwelD, VogelK, ThieleA, HenekaMT (2011) Distinct adrenergic system changes and neuroinflammation in response to induced locus ceruleus degeneration in APP/PS1 transgenic mice. Neuroscience176, 396–407.
35.
FemminellaGD, RengoG, KomiciK, IacotucciP, PetragliaL, PaganoG, de LuciaC, CanonicoV, BonaduceD, LeoscoD, FerraraN (2014) Autonomic dysfunction in Alzheimer’s disease: Tools for assessment and review of the literature. J Alzheimers Dis42, 369–377.
36.
Vander BorghtT, MinoshimaS, GiordaniB, FosterNL, FreyKA, BerentS, AlbinRL, KoeppeRA, KuhlDE (1997) Cerebral metabolic differences in Parkinson’s and Alzheimer’s diseases matched for dementia severity. J Nucl Med38, 797–802.
37.
Gonzalez-RedondoR, Garcia-GarciaD, ClaveroP, Gasca-SalasC, Garcia-EulateR, ZubietaJL, ArbizuJ, ObesoJA, Rodriguez-OrozMC (2014) Grey matter hypometabolism and atrophy in Parkinson’s disease with cognitive impairment: A two-step process. Brain137, 2356–2367.
38.
FanZ, AmanY, AhmedI, ChetelatG, LandeauB, Ray ChaudhuriK, BrooksDJ, EdisonP (2015) Influence of microglial activation on neuronal function in Alzheimer’s and Parkinson’s disease dementia. Alzheimers Dement11, 608–621. e607.
39.
FanZ, OkelloAA, BrooksDJ, EdisonP (2015) Longitudinal influence of microglial activation and amyloid on neuronal function in Alzheimer’s disease. Brain138(Pt 12), 3685–3698.
40.
DukartJ, KherifF, MuellerK, AdaszewskiS, SchroeterML, FrackowiakRS, DraganskiB, Alzheimer’s Disease Neuroimaging I (2013) Generative FDG-PET and MRI model of aging and disease progression in Alzheimer’s disease. PLoS Comput Biol9, e1002987.
41.
GerhardA, SchwarzJ, MyersR, WiseR, BanatiRB (2005) Evolution of microglial activation in patients after ischemic stroke: A [11C](R)-PK11195 PET study. Neuroimage24, 591–595.
42.
ParkKW, KimHS, CheonSM, ChaJK, KimSH, KimJW (2011) Dementia with Lewy bodies versus Alzheimer’s disease and Parkinson’s disease dementia: A comparison of cognitive profiles. J Clin Neurol7, 19–24.
43.
HildebrandtH, FinkF, KastrupA, HauptsM, ElingP (2013) Cognitive profiles of patients with mild cognitive impairment or dementia in Alzheimer’s or Parkinson’s disease. Dement Geriatr Cogn Dis Extra3, 102–112.
44.
LaaksoMP, SoininenH, PartanenK, HelkalaEL, HartikainenP, VainioP, HallikainenM, HanninenT, RiekkinenPJSr (1995) Volumes of hippocampus, amygdala and frontal lobes in the MRI-based diagnosis of early Alzheimer’s disease: Correlation with memory functions. J Neural Transm Park Dis Dement Sect9, 73–86.
45.
SmithCD, MalceinM, MeurerK, SchmittFA, MarkesberyWR, PettigrewLC (1999) MRI temporal lobe volume measures and neuropsychologic function in Alzheimer’s disease. J Neuroimaging9, 2–9.
46.
JucaiteA, CselenyiZ, ArvidssonA, AhlbergG, JulinP, VarnasK, StenkronaP, AnderssonJ, HalldinC, FardeL (2012) Kinetic analysis and test-retest variability of the radioligand [11C](R)-PK11195 binding to TSPO in the human brain - a PET study in control subjects. EJNMMI Res2, 15.
47.
LavisseS, GuillermierM, HerardAS, PetitF, DelahayeM, Van CampN, Ben HaimL, LebonV, RemyP, DolleF, DelzescauxT, BonventoG, HantrayeP, EscartinC (2012) Reactive astrocytes overexpress TSPO and are detected by TSPO positron emission tomography imaging. J Neurosci32, 10809–10818.
48.
JiB, MaedaJ, SawadaM, OnoM, OkauchiT, InajiM, ZhangMR, SuzukiK, AndoK, StaufenbielM, TrojanowskiJQ, LeeVM, HiguchiM, SuharaT (2008) Imaging of peripheral benzodiazepine receptor expression as biomarkers of detrimental versus beneficial glial responses in mouse models of Alzheimer’s and other CNS pathologies. J Neurosci28, 12255–12267.
49.
MaedaJ, HiguchiM, InajiM, JiB, HanedaE, OkauchiT, ZhangMR, SuzukiK, SuharaT (2007) Phase-dependent roles of reactive microglia and astrocytes in nervous system injury as delineated by imaging of peripheral benzodiazepine receptor. Brain Res1157, 100–111.
